Upload
melinda-sims
View
214
Download
1
Tags:
Embed Size (px)
Citation preview
Sales Trainer for PGXL Laboratories502-836-3361
Kim Dolan
© 2009 - 2014 PGXL Laboratories
The Human Genome
Human Genome Research Initiative“As important a breakthrough as understanding human anatomy”
Francis Collins, Director National Institutes of HealthGoals• Determine the sequence of chemical pairs that make up Human
DNA
• Identify and map the 25,000 genes and 3.1 million base pairs of the human genome from a physical and functional standpoint
• Understand genes and how they work to understand how diseases are caused and how best to cure them
• Switch from reacting to a disease to prevention
• 1988 – International Human Genome Initiative (HGRI) launched
• 1989 – Dr. Roland Valdes launches post-PhD Molecular Clinical Chemistry program
• 1993 – Dr. Francis Collins assumes leadership of HGRI• 1997 – Dr. Valdes and Dr. Mark Linder publish seminal
pharmacogenetics paper
Evolution of PharmacogeneticsPGXL Founders Are Pioneers in the Field
Continued…
• 2001 – PGXL Laboratories is first CLIA-certified pharmacogenetics specialist in U.S.
• 2004 – Human genome sequenced and published• 2010 – Drs. Valdes and Linder publish guidelines for
operating a pharmacogenetics laboratory
Evolution of PharmacogeneticsPGXL Founders Are Pioneers in the Field
…Continued
1. There can be wide variability in patient response to commonly prescribed medications
2. Genetics is estimated to account for 20-95% of the variability in drug effects
3. Adverse Drug Reactions (ADRs) are the 6th leading cause of death
4. A review of drugs most commonly associated with ADRs found that 57% (16 of 27) were metabolized by a gene with a known genetic polymorphism
PharmacogeneticsWhy It Matters
57% of meds in top 20 list causing ADRs are linked to a genetic variation
20-90% variability in patient response to medications can be explained by genetics
>120 drugs have FDA box warnings related to genetics
Lazarou et al. JAMA 1998; 279:1200-1205; Phillips KA et al JAMA 2001;286:2270-2279;Kalow W et al. Pharmacogenetics 1998;8:283-289
Current Situation/Implications
PharmacogeneticsSame Diagnosis, Same Medications, Different Outcomes
No VarianceNormal Response
VarianceRisk Decreased
VarianceLack of Efficacy
VarianceHigh Risk
Typical Clinic Day N=30
• Every human has a genetic code that is unique to them• There is no perfect version of the code; we all have
variants• Variances in genes responsible for drug metabolism,
transport and uptake/binding can:o Be of no consequence to the drug’s safety and efficacyo Render a medication uselesso Result in a medication causing serious adverse reactions
PharmacogeneticsThe Study of How Our Genes Affect Our Response to Drugs
Incidence of Genetic Variants Important to Drug Selection and Drug Dose
Gene % of Extensive Metabolizers
% of Intermediate Metabolizers
% of Poor Metabolizers
% of Ultra-Rapid Metabolizers VARIANTS
2D6 53% 35% 10% 2% 47%2C19 36% 32% 4% 28% 64%2C9 57% 40% 3% NA 43%VKOR >70%3A4 87% 12% 1% N/A 13%3A5 1% 18% 81% N/A 99%SLC6A4 25% 50% 25% N/A 75%
1. Pharmacogenetics Knowledge Base Implementation: www.pharmgkb.orgProperty of PGxl Laboratories
Drug group/drug No (%) of cases Individual drugs Adverse reactions
NSAIDs 363 (29.6) Aspirin (218), diclofenac (52), ibuprofen (34), rofecoxib (33), celecoxib (8), ketoprofen (6) naproxen (5)
GI bleeding, peptic ulceration, haemorrhagic cerebrovascular accident, renal impairment, wheezing, rash
Diuretics 334 (27.3) Furosemide (128), bendroflumethiazide (103), bumetanide (43), spironolactone (37), amiloride (19), metolazone (11), indapamide (6)
Renal impairment, hypotension, electrolyte disturbances, gout
Warfarin 129 (10.5) — GI bleeding, haematuria, high INR, haematoma
ACE inhibitors/All receptor antagonists
94 (7.7) Ramipril (28), enalaparil (25), captopril (12), lisinopril (9), irbesartan (6), losartan (5), perindopril (4)
Renal impairment, hypotension, electrolyte disturbance, angioedema
Antidepressants 87 (7.1) Fluoxetine (17), paroxetine (14), amitriptyline (13), citalopram (9), lithium (8), venlafaxine (8) dosulepin (7)
Confusion, hypotension, constipation, GI bleed, hyponataemia
β blockers 83 (6.8) Atenolol (69), propranolol (6), sotalol (3), bisoprolol (2), metoprolol (2), carvedilol (1)
Bradycardia, heart block, hypotension, wheezing
Opiates 73 (6.0) Morphine (20), dihydrocodeine (20), co-codamol (8), tramadol (8), co-dydramol (6), fentanyl (5)
Constipation, vomiting, confusion, urinary retention
Digoxin 36 (2.9) — Symptomatic toxic digoxin levels
Prednisolone 31 (2.5) — Gastritis, GI bleeding, hyperglycaemia, osteoporotic fracture
Clopidogrel 29 (2.4) — GI bleeding
Pirmohamed et al. BMJ 2004;329(7456):15–9.
Leading ADRs resulting in hospitalizations
State-of-the-Art -- 2014
Benefits of Molecular PGx
Guided Therapy Decision Making
Behavioral Health
Treatment Resistant Depression
Schizophrenia
CardiovascularAnti-Platelet Activation
Anti-Coagulation
Pain Management
Opioids
Patient Improvement
Cost Savings
Patient Satisfaction &Compliance
Risk Reduction
CIPHER™ strength of evidenceCV
Antiplatelet therapyAnticoagulation managementHyperlipidemiaHypertension/arrhythmia
Pain OpioidsNSAIDsMuscle relaxants
Behavioral HealthTreatment-resistant depression
(TRD)PsychosisADHD
Internal Med/GP Antithrombotic therapies
CV health (arrhythmia, lipids, stroke)Chronic pain managementType II diabetes managementGU healthAntimicrobialsMultidrug sensitivity
Oncology (under development)Colorectal cancer (KRAS, BRAF, Lynch)Breast cancer (tamoxifen)Lung Cancer (EGFR, etc)
Property of PGxl Laboratories
Personalized Medicine Program
PM Program Core Team Creation
PGxl & Client
Project Planning Meeting Schedule
Design Program
Launch and Support Program
Track and Modify
Program